Omega-3 benefits, as well as various other fish oil supplements have risen in global popularity in recent years. Believed to improve circulation around the body, omega-3 supplements are often marketed towards improving the function of the heart as well as offering relief from inflammation of conditions such as arthritis, and so have become a staple for many health-conscious vitamin routines.
Recent studies have found that a daily dose of the omega-3 benefits behaviour in children with ADHD, including poor behaviour and aggression.
Addressing unmet needs
Many parents and doctors are looking for scientifically proven, natural and safe alternatives to the current ADHD therapies, especially as a fi rst-line approach or as an additional module in a holistic therapy.
Although equazen eye q™ is not suitable as a standalone alternative to an already established drug-based ADHD therapy, for children not formally diagnosed as ADHD but with ADHD-related symptoms in attention, reading and writing, leading to suboptimal school performance, there are almost no alternatives to prescription medicines with sufficient evidence of efficacy on these issues.
Equazen and eye q™ started with a very clear goal that hasn’t changed since its launch in 2004 to provide premium omega-3 and omega-6 formulations, based on science and backed by strong independent research, to improve conditions of Attention deficit disorder (ADD) and Attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Today, eye q™ is the market leading natural supplement in in the ADHD omega-supplement field .
Eye q™ is a unique formulation
Eye q™ contains a specifically formulated blend of EPA:DHA: GLA at a ratio of 9:3:1 to effectively support brain development and function. Its specific formulation of omega-3 and omega-6 fatty acids proved effective in various clinical trials. In this specific ratio, these three essential fatty acids work most effectively to provide both structural and functional support for the central nervous
Research shows that DHA or GLA alone, or DHA in combination with low EPA levels had no positive effects on ADD/ADHD-related symptoms.1
The very low conversion efficiencies in humans strongly support the consideration of regular consumption of fatty fish, the main source of long-chain omega-3. To cover omega-3 requirements, oily fish is recommended to be included in the diet twice a week (≥ 340 g/week). Additionally or as an alternative to fish, EPA, DHA and GLA can be taken as a dietary supplement.
In a comparative study published in 2016 the following results were reported: ‘a treatment with ω-3 fatty acid DHA and EPA in combination with ω-6 fatty acids GLA or LA and vitamin E seems to be effective in treating ADHD symptoms. The treatment with 174 mg DHA, 558 mg EPA, 60 mg GLA, 9.6 or 10.8 mg vitamin E was tested in four studies, which led to promising results’.
The formulation and brand in this independent research used was eye q™. Equazen effectively supports brain development and function. Its specific formulation of polyunsaturated fatty acids EPA:DHA:GLA (Eicosapentaenoic acid, Docosahexaenoic acid, Gamma l Linolenic acid) at the ratio of 9:3:1 proved effective in various clinical trials.2,3,4 In this specific ratio, these three essential fatty acids work most effectively to provide both structural and functional support for the central nervous system.
These results back up the many positive improvements seen by parents, teachers and healthcare specialists alike.
Further research conducted by Dr. Eduardo Barragán, Pediatric Neurologist at the Hospital Infantil de México Federico Gomez, investigated the efficacy of Equazen eye q™ in ADHD patients, both as a single therapy and also in combination with methylphenidate (Ritalin).
His findings again showed significant results and he commented ‘Well, we knew that the medication methylphenidate would work fast, but in this group the problem was the side effects. I had a drop-out rate of over 25% of children in this group within the first 8 months. They simply did not tolerate the medications well. In the group taking only eye q™ I started to notice good results after about 4 to 6 weeks. I noticed that especially the ADHD inattentive type children reacted very well to this treatment option, and those with motor coordination problems too. The children had good improvements in attention, learning skills and their mood.
I was concerned initially that the Equazen eye q™ group would not maintain the study until the end, because I expected that the symptoms would not lessen and they would need medicine. But most of them stayed with eye q™ all year and improved. In the third group, taking a combination of medicine and eye q™ I had a significant finding: the children did not need as much methylphenidate as in the group without eye q™ to reach the desired result (the reduction of ADHD symptoms). This was a very important finding.
He concluded the following recommendations:
- ‘That eye q™ works very well by itself, for the inattentive type of ADHD.
- ‘That children on medication, who have side effects, could reduce these significantly, if not completely, by adding Equazen eye q™ to their medication.’
A recent randomised, double-blind, placebo-controlled trial in 9-year-old mainstream schoolchildren in Sweden was conducted to evaluate the effect of omega-3/6 fatty acids on reading in children.
The study, known as the LOGOS trial has been presented by its author, Dr. Johnson, at the ‘Jahrestagung der Schweizerische Gesellschaft für Neuropädiatrie’ congress – the annual meeting of Swiss Neuro-paediatrics Association, Solothurn, Switzerland. Over 150 Doctors, mainly Neuropsychiatric specialists and Paediatricians, attended the 2-day meeting.
The study was conducted on 154 children over a period of 6 months on 2 phases of 3 months each, and the outcomes measured the Logos test battery which is a computerised reading test based on the theory that word decoding is a central function for reading ability.5
Results have shown that Equazen eye q™ significantly improves reading ability, naming time, phonologic decoding time, visual analysis time, reading speed per word and phonologic decoding time per word when compared to placebo.
The repeated positive evidence on the specific 9: 3: 1 formulation in eye q™, as well as the fact that the fatty acids are in a re-constituted triglyceride form, affording high absorption and utilisation of these essential nutrients clearly show the true value of this specifically formulated supplement.6
We are committed to providing evidence-based premium omega formulations, perfectly suited to specific life stages, whether an expectant mother or a school-going child, our supplements support all patient to achieve their full health potential.
At SFI we believe there is a need for transparency around the quality, sourcing and process of natural healthcare products, and have distilled this philosophy into our unique Source to Patient mindset.
Caring where and how our products are sourced and made, our focused approach begins with detailed knowledge about each individual ingredient – their source, benefits, quality and consistency.
Through research, rigorous processes, quality controls and extensive product testing throughout our supply chain, we place the utmost importance in maintaining the highest standards to deliver products you can trust.
- Königs, A. Kiliaan, AJ. Critical appraisal of omega-3 fatty acids in attention-deficit/hyperactivity disorder treatment. Neuropsychiatric Disease and Treatment. 2016(12): 1869–1882
- Hussein N et al. Long-chain conversion of [13C]linoleic acid and a-linolenic acid in response to marked changes in their dietary intake in men. J. Lipid. Res. 2005; 46: 269–280.0
- Schuchardt JP et al. Signifi cance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. Eur J Pediatr 2010; 169:149–164.
- Richardson AJ and Montgomery P. The Oxford-Durham Study: A Randomized, Controlled Trial of Dietary Supplementation With Fatty Acids in Children With Developmental Coordination Disorder. Pediatrics 2005; 115(5):1360–1366.0
- Omega 3/6 fatty acids for reading in children: a randomized, double-blind, placebo-controlled trial in 9-year-old mainstream school children in Sweden .Mats Johnson, Gunnar Fransson, Sven O¨ stlund, Bjo¨rn Areskoug, and Christopher Gillberg -Journal of Child Psychology and Psychiatry (2016)
- Critical appraisal of omega-3 fatty acids in attention-defi cit/hyperactivity disorder treatment Königs Anja and Kiliaan Amanda Neuropsychiatric Disease and Treatment 2016:12 1869–1882
For additional information and resources please see our websites: